11th ICAPS Conference "Cancer Prevention:

Targeting Infection, Inflammation and the Immune System"



This is general overview of the conference, and an abbreviated outline of the sessions. For additional information, please see the conference program.


Day 1 of the conference will include 6 targeted Presentation Sessions, one of which is a Plenary Talk. Each session will have an opening speaker, and the 5 non-Plenary Talk sessions will include multiple invited speakers. Day 1 will also include a Poster Session, the first of two “Meet the Faculty” Sessions, and a Networking Reception.  One of the fundamental goals of ICAPS is to promote the development of early investigators into future leaders in cancer prevention; the “Meet the Faculty” Session was designed to provide a forum to engage young scientists in informal one-on-one discussions with international leaders in cancer prevention, which will be further supported by the Networking Reception at the close of the day’s events.


Day 2 of the conference will include 4 additional targeted Presentation Sessions, each with an opening speaker and multiple invited speakers, as well as a Selected Abstract Oral Presentations Session, a Panel Discussion, a Poster Session, and the second of the two “Meet the Faculty” Sessions.  Current research, as well as the data and perspectives shared in the Presentation Sessions and Plenary Talk, will lay the foundation for a Panel Discussion, co-chaired by Drs. Powel Brown and Mangesh Thorat at the end of Day 2 of the conference, will focus on the current state of cancer prevention strategies that target infection, inflammation, and the immune system, and the current and future potential of Phase II and III clinical trials in this field.


Special Population Early Investigator Awards:ICAPS is dedicated to the development of junior scientists from around the world into future leaders in cancer prevention. Therefore, to encourage early investigators to participate, 10 complementary registrations will be offered to: 4 delegates currently in training, 2 female, 2 disabled, and 2 representing minority communities. The selection of recipients for complementary registrations will be blinded, based upon the intrinsic quality of the research described, and reserved for participants submitting abstracts. We anticipate a significant proportion of delegates will be women and/or minorities from Europe, and will result in a high participant representation of traditionally under-represented groups.


Cancer Prevention Presentations:  Present cutting-edge results of preclinical and clinical studies of cancer prevention research targeting infection, inflammation, and the immune system.


Presentation Session 1: Targeting Inflammation

         Link Between Obesity-Inflammation and Breast Cancer

         Targeting Inflammation Pathways


Presentation Session 2:Targeting Cytokine Pathways

         Canakinumab for the Treatment and Prevention of Lung Cancer

         Targeting JAK/Stat Pathways for Cancer Prevention


Plenary Talk (Session 3):Aspirin for the prevention of cancer

         Aspirin for Cancer Prevention: Update on the ASPREE Trial

         Mechanisms by Which Aspirin Prevents Cancer


Presentation Session 4:Hepatocellular Carcinoma (HCC) Prevention

         TLR4 Inhibitors – A New Approach for Prevention of Liver Cancer

         Hepatitis B Surface Antigen (HBsAG) Vaccine and Hepatocellular Carcinoma


Presentation Session 5:Helicobacter pylori (H. Pylori) Eradication

         H. pylori Eradication for Gastric Cancer Prevention

H. pylori Eradication before Prophylactic Use of Aspirin


Presentation Session 6:Cancer Prevention Using Checkpoint Inhibitors

         PD-1 Inhibitors for Prevention of Lung Cancer

         Checkpoint Inhibitors for Treatment of Premalignant Disease


Presentation Session 7:Development of Vaccines for Cancer Prevention

         Developing Novel Vaccines for Cancer Prevention in Lynch Syndrome

         Vaccines for Prevention of Non-Viral Cancers


Presentation Session 8: Immunoprevention of Pancreatic Cancer

         Prevention of Pancreatic Cancer with an alpha-Enolase Vaccine

         Targeting Th17 Cells for the Prevention of Pancreatic Cancer


Presentation Session 9:Vaccines to Prevent Breast Cancer

         Prevention of Breast Cancer via Immunogens based on the MUC1 mucin

         Prevention of Triple-Negative DCIS Using Vaccines


Presentation Session 10:HPV Vaccines

         Preventing Cervical Cancer with the HPV Vaccine: Dose, Age, Sex

         Preventing Head and Neck Cancers with the HPV Vaccine



Networking:  Enhance interaction among cancer prevention scientists and early researchers. These interactions will promote new research collaborations, and will stimulate early career scientists and clinicians to focus on cancer prevention research, thus, propelling the field of cancer prevention forward.


Selected Abstract Oral Presentations Session: Dr. Karen Brown32,177-184, of the UK Therapeutic Cancer Prevention Network Group (UKTCPN) is co-organizing this conference, and will chair this Day 2 session featuring presentations of selected research given by students, fellows and early investigators describing results from selected abstracts.


Meet the Faculty Session:Our “Meet the Faculty Sessions” constitute one of the unique aspects of all ICAPS conferences. Two sessions (one each day) will be held to foster individual interaction between experts and international leaders in cancer prevention and junior and/or under-represented minority researchers. An innovative aspect of this session is to provide an informal setting to forge new collaborations.


Poster Walk:All individuals attending the conference will be invited to prepare an abstract outlining their current research.  Submitted abstracts will be reviewed and ranked by a ICAPS Organizing Committee.  The top 30 abstracts will be selected for oral (top 6) and poster presentations to be given on Day 1.


Welcome Cocktail and Networking Reception:  At the close of Day 1, a networking reception will be held to further foster collaborative interaction between junior and/or under-represented minority researchers and leading experts in cancer prevention.


Panel Discussion:  Evaluate current results of studies targeting infection, inflammation, and the immune system, to determine whether these results support the development of Phase II or Phase III cancer prevention clinical trials.


Panel Discussion:Drs. Brown and Thorat will chair this session, which will focus on the current and future potential for Phase II and III cancer prevention clinical trials targeting inflammatory pathways and/or the immune system for cancer prevention. The primary goals of this session are to determine whether there is sufficient evidence to support Phase II or III clinical trials, and to describe what additional results are necessary to support future Phase II and III cancer prevention trials that target infection, inflammation, and the immune system.


"Novartis Pharmaceuticals UK Ltd. are co-sponsors of this meeting. Novartis have had no involvement in the development of the meeting content, which includes the agenda and associated materials."

Rorschacherstr. 150
CH-9006 St. Gallen/Switzerland
Tel. +41 (0)71 243 00 32
Fax. +41 (0)71 245 68 05